Provided by Tiger Trade Technology Pte. Ltd.

MiNK Therapeutics, Inc.

11.00
-0.4200-3.68%
Pre-market: 11.280.2800+2.55%07:23 EDT
Volume:10.58K
Turnover:117.67K
Market Cap:56.13M
PE:-4.59
High:11.56
Open:11.56
Low:10.96
Close:11.42
52wk High:16.93
52wk Low:8.48
Shares:5.10M
Float Shares:2.07M
Volume Ratio:0.35
T/O Rate:0.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3970
EPS(LYR):-2.9257
ROE:-1238.98%
ROA:-123.84%
PB:-4.00
PE(LYR):-3.76

Loading ...

Mink Therapeutics shareholders approve KPMG as auditor

Reuters
·
Jun 23

MiNK Therapeutics Rocked by Fresh Insider Share Sale

TIPRANKS
·
Jun 06

MiNK Therapeutics director Barbara Ryan disposes of 1,500 common shares worth $19,143.25

Reuters
·
Jun 06

MiNK Therapeutics announces virtual annual shareholders meeting

Reuters
·
Jun 04

MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting

GlobeNewswire
·
Jun 04

BUZZ-U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl's

Reuters
·
May 29

MiNK Therapeutics doses first patient in agenT-797 trial

TIPRANKS
·
May 28

BUZZ-MiNK Therapeutics jumps after first patient dosed in lung injury study

Reuters
·
May 28

Mink Therapeutics doses first patient in Phase 2 agenT-797 acute lung injury trial

Reuters
·
May 28

Mink Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of Agent-797 in Acute Lung Injury and Critical Illness

THOMSON REUTERS
·
May 28

MiNK Therapeutics reports new data on agenT-797 at ATS 2026

TIPRANKS
·
May 20

Mink Therapeutics starts Phase 2 trial of agenT-797 in severe acute lung injury

Reuters
·
May 20

MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications

GlobeNewswire
·
May 20

MiNK Therapeutics Price Target Maintained With a $35.00/Share by HC Wainwright & Co.

Dow Jones
·
May 18

Analysts Are Bullish on These Healthcare Stocks: Biofrontera (BFRI), MiNK Therapeutics (INKT)

TIPRANKS
·
May 18

Mink Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 16

MiNK Therapeutics Q1 EPS $(0.57) Beats $(0.78) Estimate

Benzinga Earnings
·
May 15

MiNK Therapeutics Q1 FY26 net loss narrows to $2.74 million

Reuters
·
May 15

BRIEF-MiNK Therapeutics Q1 EPS USD -0.57

Reuters
·
May 15

Mink Therapeutics Q1 EPS USD -0.57

THOMSON REUTERS
·
May 15